Form 4: Kiniksa Pharmaceuticals Insider Trading Activity

Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals, reported transactions involving Class A Ordinary Shares and Restricted Share Units.

Summary

• Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals International, plc, reported transactions on April 7, 2026.
• He acquired 2,694 Class A Ordinary Shares through the vesting of Restricted Share Units (RSUs).
• Following this acquisition, Ragosa beneficially owns 17,457 Class A Ordinary Shares directly.
• Additionally, he disposed of 1,303 Class A Ordinary Shares at a price of $48.94 per share, retaining 16,154 shares directly.
• The RSUs vest over a four-year period, with 25% vesting annually, starting from the grant date of April 7, 2022.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transactions reflect standard RSU vesting and a partial sale, with the CFO's overall beneficial ownership remaining substantial.

Positives

• The Chief Financial Officer continues to hold a significant number of shares (16,154) after the reported transactions.
• The acquisition of shares through RSUs indicates continued equity-based compensation and potential alignment with company performance.

Negatives

• The disposal of 1,303 shares by the CFO could be interpreted as a reduction in direct ownership, although the net effect on total holdings is positive due to RSU vesting.

Future Outlook

The RSUs vest over a four-year period, with 25% vesting annually, indicating a continued gradual increase in the CFO's shareholding over the next few years, assuming continued employment and vesting conditions are met.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for tracking insider transactions in the pharmaceutical sector, providing transparency on executive stock holdings and potential trading activity.

Stakeholder Impact

• Shareholders: Increased transparency into insider holdings and potential selling pressure, though offset by RSU vesting.
• Employees: The RSU vesting schedule reinforces the company's use of equity as a long-term incentive.

Next Steps

• Continued vesting of Restricted Share Units over the next three years.
• Potential future transactions by the reporting person based on personal financial planning and company performance.

Key Dates

Keywords

Form 4, Insider Trading, Kiniksa Pharmaceuticals, KNSA, Class A Ordinary Share, Restricted Share Units, RSU Vesting, Beneficial Ownership, Mark Ragosa, Chief Financial Officer